logo-loader
viewC4X Discovery Holdings PLC

C4X Discovery - Notice of AGM and Posting of 2019 Annual Report

RNS Number : 0962A
C4X Discovery Holdings PLC
17 January 2020
 

C4X Discovery Holdings plc

 

("C4XD", "C4X Discovery" or the "Company")

 

Notice of Annual General Meeting and Posting of 2019 Annual Report

 

 

17 January 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces that the Annual General Meeting of the Company will be held on 31 January 2020, at 11:00am, at Panmure Gordon, One New Change, LondonThe Annual Report and Financial Statements for the year ended 31 July 2019, has been published and sent to shareholders.

 

A copy of the 2019 Annual Report can be viewed on, and downloaded from, the Company's website at https://www.c4xdiscovery.com.

 

 

- Ends -

 

 

Contacts

 

C4X Discovery Holdings


Mo Noonan, Communications

+44 (0)787 6444977



Panmure Gordon (UK) Limited (NOMAD and Broker)

 

Freddy Crossley, Emma Earl (Corporate Finance)

+44 (0)20 7886 2500

James Stearns (Corporate Broking)




C4X Discovery Media - Consilium Strategic Communications


Mary-Jane Elliott, Chris Gardner, Matthew Neal

+44 (0)203 709 5700

 

 

Notes to Editors:

 

About C4X Discovery

C4X Discovery (C4XD) aims to create the world's most productive Drug Discovery engine by using cutting-edge technologies and expertise to efficiently deliver best-in-class small-molecule medicines to clinical partners for the benefit of patients. The Company's business model focuses on replenishing big pharma discovery pipelines and driving returns through revenue generating pre-clinical licensing deals. In 2018, C4XD successfully out-licensed a pre-clinical programme in addictive disorders to Indivior in a deal worth up to $294m.

 

C4XD has a state-of-the-art suite of proprietary technologies across the Drug Discovery process and accesses further innovative capabilities and expertise through its growing network of partners. The Company is actively advancing its diverse pre-clinical discovery portfolio which is focused on inflammation, neurodegeneration and oncology (including immuno-oncology). Opportunities to maximise value from the portfolio are proactively driven by C4XD's commercial division. The Company is led by a highly experienced management team and Board who have delivered significant value creation within the healthcare sector.

 

For additional information please go to: www.c4xdiscovery.com

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCBFMBTMTTBTMM

Quick facts: C4X Discovery Holdings PLC

Price: 11.75

Market: AIM
Market Cap: £12.73 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: C4X Discovery fully cashed up and sees big potential for its...

C4X Discovery Holdings plc's (LON:C4XD) Clive Dix speaks to Proactive London's Andrew Scott following the news they've raised around £6.6mln to strengthen its balance sheet amid ongoing licensing discussions for its early-stage drug candidates. While expressing regret for the level at which...

on 25/10/19